These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 20022911)

  • 21. Overall survival after immunotherapy, tyrosine kinase inhibitors and surgery in treatment of metastatic renal cell cancer: outcome of 143 consecutive patients from a single centre.
    De Lichtenberg TH; Hermann GG; Rørth M; Højer Larsen MJ; Mansourvar Z; Holm ML; Scheike T
    Scand J Urol; 2014 Aug; 48(4):379-86. PubMed ID: 24521185
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A combined biomarker pattern improves the discrimination of lung cancer.
    Liu L; Liu J; Wang Y; Dai S; Wang X; Wu S; Wang J; Huang L; Xiao X; He D
    Biomarkers; 2011 Feb; 16(1):20-30. PubMed ID: 20964562
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preoperative apolipoprotein B/A1 ratio is an independent prognostic factor in metastatic renal cell carcinoma.
    Zhang F; Xie Y; Ma X; Gu L; Li H; Li X; Guo G; Zhang X
    Urol Oncol; 2019 Mar; 37(3):184.e9-184.e17. PubMed ID: 30509867
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model.
    de Velasco G; Culhane AC; Fay AP; Hakimi AA; Voss MH; Tannir NM; Tamboli P; Appleman LJ; Bellmunt J; Kimryn Rathmell W; Albiges L; Hsieh JJ; Heng DY; Signoretti S; Choueiri TK
    Oncologist; 2017 Mar; 22(3):286-292. PubMed ID: 28220024
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Significance of serum amyloid A on the prognosis in patients with renal cell carcinoma.
    Kimura M; Tomita Y; Imai T; Saito T; Katagiri A; Ohara-Mikami Y; Matsudo T; Takahashi K
    Cancer; 2001 Oct; 92(8):2072-5. PubMed ID: 11596022
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum amyloid A as indicator of distant metastases but not as early tumor marker in patients with renal cell carcinoma.
    Ramankulov A; Lein M; Johannsen M; Schrader M; Miller K; Loening SA; Jung K
    Cancer Lett; 2008 Sep; 269(1):85-92. PubMed ID: 18504068
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Utilizing pre-therapy clinical schema and initial CT changes to predict progression-free survival in patients with metastatic renal cell carcinoma on VEGF-targeted therapy: a preliminary analysis.
    Smith AD; Shah SN; Rini BI; Lieber ML; Remer EM
    Urol Oncol; 2013 Oct; 31(7):1283-91. PubMed ID: 21956044
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Monomeric calgranulins measured by SELDI-TOF mass spectrometry and calprotectin measured by ELISA as biomarkers in arthritis.
    de Seny D; Fillet M; Ribbens C; Marée R; Meuwis MA; Lutteri L; Chapelle JP; Wehenkel L; Louis E; Merville MP; Malaise M
    Clin Chem; 2008 Jun; 54(6):1066-75. PubMed ID: 18436720
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of glandular metastases on overall survival of patients with metastatic clear cell renal cell carcinoma in the antiangiogenic therapy era.
    Gravis G; Chanez B; Derosa L; Beuselinck B; Barthelemy P; Laguerre B; Brachet PE; Joly F; Escudier B; Harrison DJ; Laird A; Vasudev N; Ralph C; Larkin J; Lote H; Salem N; Walz J; Thomassin J; Sfumato P; Stewart GD; Boher JM;
    Urol Oncol; 2016 Apr; 34(4):167.e17-23. PubMed ID: 26670200
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The association of hematologic parameters on the prognosis of patients with metastatic renal cell carcinoma.
    Dirican A; Kucukzeybek Y; Somali I; Erten C; Demir L; Can A; Bahriye Payzin K; Vedat Bayoglu I; Akyol M; Koseoglu M; Alacacioglu A; Oktay Tarhan M
    J BUON; 2013; 18(2):413-9. PubMed ID: 23818354
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Proteomic analysis reveals differentially secreted proteins in the urine from patients with clear cell renal cell carcinoma.
    Sandim V; Pereira Dde A; Kalume DE; Oliveira-Carvalho AL; Ornellas AA; Soares MR; Alves G; Zingali RB
    Urol Oncol; 2016 Jan; 34(1):5.e11-25. PubMed ID: 26420021
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic value of the Glasgow Prognostic Score for patients with metastatic renal cell carcinoma treated by cytoreductive nephrectomy.
    Fukuda H; Takagi T; Kondo T; Yoshida K; Shimizu S; Nagashima Y; Tanabe K
    Int J Clin Oncol; 2018 Jun; 23(3):539-546. PubMed ID: 29302841
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Application of SELDI-TOF-MS to identify serum biomarkers for renal cell carcinoma.
    Xu G; Xiang CQ; Lu Y; Kang XN; Liao P; Ding Q; Zhang YF
    Cancer Lett; 2009 Sep; 282(2):205-13. PubMed ID: 19362769
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Validation of SELDI-TOF MS serum protein profiles for renal cell carcinoma in new populations.
    Engwegen JY; Mehra N; Haanen JB; Bonfrer JM; Schellens JH; Voest EE; Beijnen JH
    Lab Invest; 2007 Feb; 87(2):161-72. PubMed ID: 17318195
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum apolipoprotein C-II is prognostic for survival after pancreatic resection for adenocarcinoma.
    Xue A; Chang JW; Chung L; Samra J; Hugh T; Gill A; Butturini G; Baxter RC; Smith RC
    Br J Cancer; 2012 Nov; 107(11):1883-91. PubMed ID: 23169340
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic and predictive value of hematologic parameters in patients with metastatic renal cell carcinoma: second line sunitinib treatment following IFN-alpha.
    Dirican A; Kucukzeybek Y; Erten C; Somali I; Demir L; Can A; Payzin KB; Bayoglu IV; Akyol M; Yildiz Y; Koeseoglu M; Alacacioglu A; Tarhan MO
    Asian Pac J Cancer Prev; 2013; 14(3):2101-5. PubMed ID: 23679326
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Proteomic Analysis of Serum Amyloid A as a Potential Marker in Intestinal Behçet's Disease.
    Lee HJ; Kim JH; Kim SW; Joo HA; Lee HW; Kim YS; Park SJ; Hong SP; Kim TI; Kim WH; Kim YH; Cheon JH
    Dig Dis Sci; 2017 Aug; 62(8):1953-1962. PubMed ID: 28523576
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic impact of baseline serum C-reactive protein in patients with metastatic renal cell carcinoma (RCC) treated with sunitinib.
    Beuselinck B; Vano YA; Oudard S; Wolter P; De Smet R; Depoorter L; Teghom C; Karadimou A; Zucman-Rossi J; Debruyne PR; Van Poppel H; Joniau S; Lerut E; Strijbos M; Dumez H; Paridaens R; Van Calster B; Schöffski P
    BJU Int; 2014 Jul; 114(1):81-9. PubMed ID: 24215209
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hyponatremia as a prognostic and predictive factor in metastatic renal cell carcinoma.
    Jeppesen AN; Jensen HK; Donskov F; Marcussen N; von der Maase H
    Br J Cancer; 2010 Mar; 102(5):867-72. PubMed ID: 20145619
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Body mass index and age are additional prognostic factors in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors.
    Song Y; Du C; Zhang W; Sun Y; Yang L; Cui C; Chi Y; Shou J; Zhou A; Wang J; Sun Y
    Urol Oncol; 2016 Jun; 34(6):258.e15-22. PubMed ID: 26803435
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.